Guggenheim analyst Michael Schmidt last night downgraded Bolt Biotherapeutics to Neutral from Buy without a price target following the company’s decision to discontinue development of its lead product candidate, BDC-1001. While Bolt has two additional product candidates, BDC-3042 and BDC-4182 in development, visibility on their probability of success is low, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BOLT: